Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 14/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 13/20 | 0.47 |
| ▸ | MMP2 | P08253 | 8/20 | 0.47 |
| ▸ | MMP13 | P45452 | 5/20 | 0.47 |
| ▸ | MMP14 | P50281 | 4/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.47 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069855 | 1.00 | ADAMTS5 (0.47) | ADAMTS5ADAM17MMP2MMP13MMP14 | |
| SCHEMBL7068679 | 0.90 | CHIA (0.48) | LMNAMC4R | |
| SCHEMBL7068676 | 0.90 | CHIA (0.48) | LMNAMC4R | |
| SCHEMBL7069253 | 0.89 | LMNA (0.55) | LMNATSHRMAPK1RECQLNPSR1 | |
| SCHEMBL7069249 | 0.89 | LMNA (0.55) | LMNATSHRMAPK1RECQLNPSR1 | |
| SCHEMBL7069345 | 0.87 | MAPT (0.52) | LMNATSHRMAPK1RECQLNPSR1 | |
| SCHEMBL7069348 | 0.87 | MAPT (0.52) | LMNATSHRMAPK1RECQLNPSR1 | |
| SCHEMBL7087655 | 0.85 | GAA (0.51) | LMNATSHRMAPK1RECQLNPSR1 | |
| SCHEMBL7087657 | 0.85 | GAA (0.51) | LMNATSHRMAPK1RECQLNPSR1 | |
| SCHEMBL6955270 | 0.84 | USP2 (0.49) | TSHRNPSR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | ADAMTS5 3040/4885ADAM17 625/4885MMP2 3975/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | ADAMTS5 3040/4885ADAM17 625/4885MMP2 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.